JEFF HARPER — Lobbyist Profile | Poliscope

JEFF HARPER

Filings

Clients

Firms

Years active

2023–2026

Associated filing income

$200,000

How to read the money

Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.

Clients represented

Client	Filings	Years
NATIONAL STEM CELL FOUNDATION	13	2023–2026
Inotiv, Inc.	12	2023–2026

Lobbying firms

Firm	Filings	Years
MCCARTHY STRATEGIC SOLUTIONS	25	2023–2026

Original LDA source filings (25)

Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.

NATIONAL STEM CELL FOUNDATION via MCCARTHY STRATEGIC SOLUTIONS

2026 · third_quarter · Q3

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Stem cell research and funding.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

INOTIV, INC. via MCCARTHY STRATEGIC SOLUTIONS

2026 · third_quarter · Q3

Firm income: $11,250Client expense: —Open original LDA filing ↗

Source: Senate LDA

Show 21 more original filings

NATIONAL STEM CELL FOUNDATION via MCCARTHY STRATEGIC SOLUTIONS

2026 · first_quarter · Q1

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Stem cell research and funding.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

INOTIV, INC. via MCCARTHY STRATEGIC SOLUTIONS

2026 · first_quarter · Q1

Firm income: $11,250Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

ANI

Animals

Anima research models to biopharmaceuticals, academic and government research for realizing life saving medication.

MED

Medical/Disease Research/Clinical Labs

Animal research models to biopharmaceuticals, academic and government research for realizing life-saving medications.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

NATIONAL STEM CELL FOUNDATION via MCCARTHY STRATEGIC SOLUTIONS

2025 · fourth_quarter · Q4

Firm income: $5,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Stem cell research and funding.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

INOTIV, INC. via MCCARTHY STRATEGIC SOLUTIONS

2025 · fourth_quarter · Q4

Firm income: $11,250Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

ANI

Animals

Anima research models to biopharmaceuticals, academic and government research for realizing life saving medication.

MED

Medical/Disease Research/Clinical Labs

Animal research models to biopharmaceuticals, academic and government research for realizing life-saving medications.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

NATIONAL STEM CELL FOUNDATION via MCCARTHY STRATEGIC SOLUTIONS

2025 · third_quarter · Q3

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Stem cell research and funding.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

INOTIV, INC. via MCCARTHY STRATEGIC SOLUTIONS

2025 · third_quarter · Q3

Firm income: $11,250Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

ANI

Animals

Anima research models to biopharmaceuticals, academic and government research for realizing life saving medication.

MED

Medical/Disease Research/Clinical Labs

Animal research models to biopharmaceuticals, academic and government research for realizing life-saving medications.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

NATIONAL STEM CELL FOUNDATION via MCCARTHY STRATEGIC SOLUTIONS

2025 · second_quarter · Q2

Firm income: $5,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Stem cell research and funding.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

INOTIV, INC. via MCCARTHY STRATEGIC SOLUTIONS

2025 · second_quarter · Q2

Firm income: $11,250Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

MED

Medical/Disease Research/Clinical Labs

Animal research models to biopharmaceuticals, academic and government research for realizing life-saving medications.

ANI

Animals

Anima research models to biopharmaceuticals, academic and government research for realizing life saving medication.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

NATIONAL STEM CELL FOUNDATION via MCCARTHY STRATEGIC SOLUTIONS

2025 · first_quarter · Q1

Firm income: $5,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Stem cell research and funding.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

INOTIV, INC. via MCCARTHY STRATEGIC SOLUTIONS

2025 · first_quarter · Q1

Firm income: $11,250Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

ANI

Animals

Anima research models to biopharmaceuticals, academic and government research for realizing life saving medication.

MED

Medical/Disease Research/Clinical Labs

Animal research models to biopharmaceuticals, academic and government research for realizing life-saving medications.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

NATIONAL STEM CELL FOUNDATION via MCCARTHY STRATEGIC SOLUTIONS

2024 · fourth_quarter · Q4

Firm income: $15,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to stem cell research.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

INOTIV, INC. via MCCARTHY STRATEGIC SOLUTIONS

2024 · fourth_quarter · Q4

Firm income: $11,250Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

ANI

Animals

Animal research models to biopharmaceuticals, academic and government research for realizing life-saving medication.

MED

Medical/Disease Research/Clinical Labs

Animal research models to biopharmaceuticals, academic and government research for realizing life saving medications

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

NATIONAL STEM CELL FOUNDATION via MCCARTHY STRATEGIC SOLUTIONS

2024 · third_quarter · Q3

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to stem cell research.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

INOTIV, INC. via MCCARTHY STRATEGIC SOLUTIONS

2024 · third_quarter · Q3

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

ANI

Animals

Animal research models to biopharmaceuticals, academic and government research for realizing life-saving medication.

MED

Medical/Disease Research/Clinical Labs

Animal research models to biopharmaceuticals, academic and government research for realizing life saving medications

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

NATIONAL STEM CELL FOUNDATION via MCCARTHY STRATEGIC SOLUTIONS

2024 · second_quarter · Q2

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to stem cell research.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

INOTIV, INC. via MCCARTHY STRATEGIC SOLUTIONS

2024 · second_quarter · Q2

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

ANI

Animals

Animal research models to biopharmaceuticals, academic and government research for realizing life-saving medication.

MED

Medical/Disease Research/Clinical Labs

Animal research models to biopharmaceuticals, academic and government research for realizing life saving medications

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

NATIONAL STEM CELL FOUNDATION via MCCARTHY STRATEGIC SOLUTIONS

2024 · first_quarter · Q1

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to stem cell research.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

INOTIV, INC. via MCCARTHY STRATEGIC SOLUTIONS

2024 · first_quarter · Q1

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MED

Medical/Disease Research/Clinical Labs

Animal research models to biopharmaceuticals, academic and government research for realizing life saving medications

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

NATIONAL STEM CELL FOUNDATION via MCCARTHY STRATEGIC SOLUTIONS

2023 · fourth_quarter · 4A

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Issues related to stem cell research.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

INOTIV, INC. via MCCARTHY STRATEGIC SOLUTIONS

2023 · fourth_quarter · 4A

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MED

Medical/Disease Research/Clinical Labs

Animal research models to biopharmaceuticals, academic and government research for realizing life saving medications

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

NATIONAL STEM CELL FOUNDATION via MCCARTHY STRATEGIC SOLUTIONS

2023 · fourth_quarter · RR

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (2 issues)

BUD

Budget/Appropriations

research funding

HCR

Health Issues

research funding